MedImmune Completes Cellective Acquisition
The transaction provides MedImmune with three preclinical-stage programs developing monoclonal antibodies targeting the B-cell antigens CD19, CD20 and CD22. These antigens are believed to play important roles in regulating the immune system with potential implications in both cancer and autoimmune diseases.
In September 2005, MedImmune signed a definitive agreement to acquire Cellective Therapeutics, Inc. in a cash transaction that includes an upfront payment and the potential for future milestones, all of which could total up to approximately $160 million if all contingencies are met. Under the terms of the agreement, MedImmune will make milestone payments to Cellective shareholders based upon achieving certain product development and sales goals for Cellective's preclinical antibody programs targeting CD19, CD20 and CD22. MedImmune's relationship with Cellective Therapeutics began in September 2004 when MedImmune Ventures, Inc. participated in Cellective's Series A financing round.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous